(NASDAQ: ACXP) Acurx Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.22%.
Acurx Pharmaceuticals's earnings in 2026 is -$7,506,221.On average, 5 Wall Street analysts forecast ACXP's earnings for 2026 to be -$8,725,935, with the lowest ACXP earnings forecast at -$10,329,045, and the highest ACXP earnings forecast at -$5,644,085. On average, 5 Wall Street analysts forecast ACXP's earnings for 2027 to be -$8,134,650, with the lowest ACXP earnings forecast at -$9,812,593, and the highest ACXP earnings forecast at -$5,754,754.
In 2028, ACXP is forecast to generate -$9,514,315 in earnings, with the lowest earnings forecast at -$9,812,593 and the highest earnings forecast at -$9,074,804.